Entecavir Versus Lamivudine for Preventing the Risk of Hepatitis B Reactivation in NHL

• Status: Unknown status
• Trial end date: 2016-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study is to prove the superiority of entecavir over lamivudine for preventing the risk of hepatitis B virus reactivation in patients with non-Hodgkin lymphoma on CHOP/R-CHOP.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Fudan University
• Treatments: Entecavir; Lamivudine

Criteria

Inclusion Criteria:

• Previously untreated NHL suitable for CHOP/R-CHOP treatment

• Age range 18-80 years old

• HBsAg positive with high level of HBV DNA

• Eastern Cooperative Oncology Group performance status 0-2

• Life expectancy of more than 3 months

• Adequate organ function

Exclusion Criteria:

• Primary or secondary central nervous system involvement

• With hepatitis C virus infection

• Previous serious cardiac disease

• History of other malignancies except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix

• Pregnant or lactating women

• Serious uncontrolled diseases and intercurrent infection